A Randomized Phase III Study Comparing Etoposide and Cisplatin with Etoposide, Cisplatin and Paclitaxel in Patients with Extensive Small Cell Lung Cancer

Patients must have histologically or cytologically confirmed diagnosis of extensive SCLC; pts. must have measurable or evaluable dz; pleural effusions, bone scan abnormalities, and bone marrow biopsies are neither measurable nor evaluable (pts with these findings are eligible for this study but they must have an additional site of measurable or evaluable dz); no prior chemo for SCLC; no prior pelvic or mediastinal RT; PS 0-1; AGC >=1,500/ul, PLTS >=100,000/ul, serum creatinine <=1.5 mg/dl, bilirubin <1.5 mg/dl, SGOT (AST) <2 x IULN.